BioSpace News Archive

Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended September 30, 2020. “Over the last quarter, we have demonstrated the unique capability of our platform to translate the immune response at scale into data

-- Received Notice from the FDA that the SYN-004 (ribaxamase) Phase 1b/2a Clinical Program in Adult Allogeneic HCT Recipients May Proceed as Planned; Trial Commencement Anticipated in Q1 2021 -- -- Received Study-May-Proceed Letter from the FDA Supporting a Phase 1 Single Ascending Dose Study of SYN-020 IAP; Phase 1 Study to Support Development of SYN-020 in Multiple Indications -- Conference Call Today at 4:30 p.m. (ET) --

All 3 efficacy endpoints in the Global Phase 2 FIGHT trial met pre-specified statistical significance Median progression-free survival (PFS) improved from 7.4 months to 9.5 months. Hazard ratio (HR) 0.68 (95% CI: 0.44-1.04) p=0.073 Median overall survival (OS) improved from 12.9 months to not reached. HR 0.58 (95% CI: 0.35-0.95) p=0.027 Overall response rate (ORR) improved by 13.1% (p=0.106)

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will present a company overview at the Jefferies Virtual London Healthcare Conference on Nov. 18. Dr. Countouriotis’ session is scheduled to begin at 12:35 p.m. ET and will be accessible via webcast through the Investors page of

Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer is scheduled to present at the Jefferies Virtual London Healthcare Conference. Details of the presentation are as follows: Event: Jefferies Virtual London Healthcare Conference Format: Fireside Chat and 1x1 Meetings Fireside Chat Date: Tuesday, November 17, 2020 Firesi

Nadia Roan, PhD, who first came to Gladstone Institutes as a postdoctoral scholar in 2007 and has been a visiting scientist since 2012, is now joining the biomedical research institution as an associate investigator.

BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer, will participate in the following upcoming investor conferences. Event: H.C. Wainwright 6th Annual Israel Conference (Virtual) Date: Thursday, Nov. 12, 2020 Time: 9:30 a.m. EST Webcast link: BiomX

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, will present a company overview at the Stifel Virtual Healthcare Conference on Tuesday, November 17, 2020 at 2:40 p.m. ET. A live audio webcast of the presentation will be available on Geron’s website, www.geron.com/investors/events . If you are un

The stakes have never been higher for the millions of Californians who rely on the Affordable Care Act for access to the vital health care services they and their loved ones count on every day.

Inogen, Inc. (NASDAQ: INGN ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the Company’s management will be participating in the Stifel 2020 Virtual Healthcare Conference. Inogen’s President and CEO, Scott Wilkinson, and CFO, Alison Bauerlein, are scheduled to present on Tuesday, November 17 th , 2020 at 4:00 p.m. EST at the Stifel 2020